Raymond J. March
Assistant Professor of Economics, Angelo State University
Raymond J. March
Research Fellow and Director of FDAReview.org
Raymond J. March is a Research Fellow and Director of FDAReview.org with the Independent Institute. He is also an Assistant Professor of Economics at Angelo State University where he is the Assistant Director of the Free Market Institute, Assistant Research Professor at Texas Tech University, Public Choice and Public Policy fellow with the American Institute for Economic Research, and an affiliated scholar with the Challey Institute for Global Innovation and Growth.
Read Full BioActive Filters
Active Filters
{content}Custom Date Range
Publication Type
Content Type
Multimedia Type
Issues
Active Filters
Active Filters
{content}The “Warp Speed” That Worked Best
Maurice Hilleman’s vaccine development in 1957 shows what's possible with freer biomedical innovation.
Copycat Pharmacies and the Peptide Market
The emerging compounding ecosystem can drive faster development and wider availability when allowed.
Mark Cuban and Healthcare Competition
Market competition accomplishes what decades of regulation haven't
Artificial Intelligence Collides with FDA Bureaucracy
The FDA’s latest AI rollout reveals more about politics than innovation
Right-to-Try Laws Could Increase Gene Therapy Access
State reforms could expand patient access to personalized gene therapies while federal approval lags.
The Blueprint for a Bigger Medical Bureaucracy, Part 3
Part 3 of a series arguing that the best FDA reforms come from markets, not larger government.
The Blueprint for a Bigger Medical Bureaucracy, Part 2
Part 2 of a series exploring why crisis-era policymaking is a poor model for lasting FDA reform.
The Blueprint for a Bigger Medical Bureaucracy
Part 1 of a series examining the contradictions in a major proposal to reform the FDA.
Hantavirus Shows How Little Has Changed
Angela Perryman thought she was doing the right thing. After a hantavirus outbreak killed...
The FDA Can’t Manage Its Own Risk Problem
Risk management is the leading reason the Food and Drug Administration cites...
